PRECISION BIOSCIENCES INC
DTIL evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for DTIL—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · DTIL
Precision BioSciences Inc. is a clinical-stage biotechnology company developing in vivo gene editing therapies using its proprietary ARCUS platform, with lead programs in chronic hepatitis B (PBGENE-HBV) and Duchenne muscular dystrophy (PBGENE-DMD). As of June 30, 2026, the company held $112.4 million in cash and equivalents, reported no revenue, and posted a net loss of $32.7 million for the quarter.
Key risk: No approved products or revenue
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 3 pipeline candidates · 14 clinical trials · 6 FDA decisions for PRECISION BIOSCIENCES INC.
Precision BioSciences Inc. is a clinical-stage biotechnology company developing in vivo gene editing therapies using its proprietary ARCUS platform, with lead programs in chronic hepatitis B (PBGENE-HBV) and Duchenne muscular dystrophy (PBGENE-DMD). As of June 30, 2026, the company held $112.4 million in cash and equivalents, reported no revenue, and posted a net loss of $32.7 million for the quarter.
- Lead programs PBGENE-HBV (chronic hepatitis B) and PBGENE-DMD (Duchenne muscular dystrophy) are in clinical development [sec · filed 2026-01-13].
- Cash and equivalents of $112.4M as of 2026-06-30; net loss of $32.7M for the same period; no revenue reported [sec].
- Company expects cash runway through 2028, supported by existing cash, potential milestone payments, fiscal discipline, and an at-the-market facility [sec · filed 2026-01-13].
- Phase 1/2 DMD trial expected to dose first patient in late-Q1/early-Q2 2026, with initial data by year-end 2026 [sec · filed 2026-01-13].
- HBV program includes paired biopsies to assess gene editing and cccDNA elimination [sec · filed 2025-11-10].
What works
- Proprietary ARCUS gene-editing platform supports multiple in vivo programs, potentially enabling durable one-time treatments [sec_mda · as of 2026-03-12].
- Cash runway projected through 2028, providing multi-year operational visibility without near-term financing pressure [sec · filed 2026-01-13].
- Multiple clinical catalysts expected in 2026, including initial DMD data and HBV program progress [sec · filed 2026-01-13].
What to weigh
- No approved products or revenue; company has incurred significant operating losses since inception [sec_mda · as of 2026-03-12].
- Clinical-stage biotech with high development risk; success depends on clinical trial outcomes and regulatory approvals [sec_mda · as of 2026-03-12].
- Future capital needs remain uncertain; additional financing may be required if milestones are delayed or partnerships not secured [sec_mda · as of 2026-03-12].
From the filings
Quoted directly from source documents.
Cash runway through 2028
“existing cash and cash equivalents, inclusive of the expected azer-cel milestone proceeds, continued fiscal and operating discipline, and availability of our ATM facility will be sufficient to fund our operating expenses and capital expenditure requirements through 2028.”
SEC MD&A · March 12, 2026
DMD trial first patient dosing and data timeline
“DMD Phase 1/2 clinical trial in Duchenne muscular dystrophy patients is expected to dose the first patient in late-Q1 or early-Q2 2026. Initial data from multiple patients is expected by year end 2026.”
SEC filings · January 13, 2026
HBV program includes paired biopsies for gene editing evidence
“Paired biopsies are expected to be conducted in all patients in Part 2 in order to provide robust biologic evidence of gene editing at the root viral source of the disease and cccDNA elimination.”
SEC filings · November 10, 2025
Cash position as of December 31, 2025
“As of December 31, 2025, we had cash and cash equivalents of $110.8 milli”
SEC MD&A · March 12, 2026
Risks & what to watch (3)›
Key risks
- No approved products or revenue — Company has no commercial products and has incurred significant operating losses since inception; future revenue is uncertain [sec_mda · as of 2026-03-12].
- Clinical and regulatory uncertainty — Success depends on positive clinical trial results and regulatory approvals, which are inherently unpredictable [sec_mda · as of 2026-03-12].
- Future capital needs — Additional financing may be required if milestones are delayed or partnerships not secured; terms may be unfavorable [sec_mda · as of 2026-03-12].
What to watch
- Initial patient dosing and data readout from the DMD Phase 1/2 trial, expected by year-end 2026 [sec · filed 2026-01-13].
- Progress and data from the PBGENE-HBV ELIMINATE-B trial, including paired biopsy results [sec · filed 2025-11-10].
- Cash burn rate and any updates to cash runway guidance, especially if milestones are delayed [sec_mda · as of 2026-03-12].
- Potential partnership or licensing deals to fund pipeline advancement [sec_mda · as of 2026-03-12].
Sources: Catalysts · SEC filings · SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run PRECISION BIOSCIENCES INC through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available PRECISION BIOSCIENCES INC facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
25.4 months
D/E 1.78 · 0% dilution
Lead: Approved
3 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
74
Total value held
$48.5M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 1,821,480 | $10.0M |
| boothbay fund management, llc | 1,066,050 | $5.9M |
| driehaus capital management llc | 995,371 | $5.5M |
| lynx1 capital management lp | 985,113 | $5.4M |
| affinity asset advisors, llc | 597,946 | $3.3M |
| marshall wace, llp | 415,671 | $2.3M |
| two sigma investments, lp | 307,790 | $1.7M |
| geode capital management, llc | 287,090 | $1.6M |
| renaissance technologies llc | 223,177 | $1.2M |
| blackrock, inc. | 199,761 | $1.1M |
Showing top 10 of 74 institutional holders of PRECISION BIOSCIENCES INC. Open the full 13F history after sign-in.
Short Interest
as of Apr 20, 2026- % of float
- 4.7%
- Days to cover
- 3.1
- Shares short
- 1,171,027
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
DTIL short interestGovernance
Frequently asked questions
What is the AI investment thesis for PRECISION BIOSCIENCES INC?
Precision BioSciences Inc. is a clinical-stage biotechnology company developing in vivo gene editing therapies using its proprietary ARCUS platform, with lead programs in chronic hepatitis B (PBGENE-HBV) and Duchenne muscular dystrophy (PBGENE-DMD). As of June 30, 2026, the company held $112.4 million in cash and equivalents, reported no revenue, and posted a net loss of $32.7 million for the quarter.
What is PRECISION BIOSCIENCES INC's lead drug candidate?
PRECISION BIOSCIENCES INC's most advanced tracked candidate is fosfomycin (Approved).
Who is the CEO of PRECISION BIOSCIENCES INC?
Mr. Michael Amoroso is the chief executive officer of PRECISION BIOSCIENCES INC (DTIL).
Where is PRECISION BIOSCIENCES INC headquartered?
PRECISION BIOSCIENCES INC (DTIL) is headquartered in Durham, NC, United States.
What therapeutic areas does PRECISION BIOSCIENCES INC focus on?
PRECISION BIOSCIENCES INC develops therapies across Oncology, Rare Disease, Gene Therapy, Infectious Disease, Dermatology, Musculoskeletal.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.